EU/3/20/2264

About

On 24 March 2020, orphan designation EU/3/20/2264 was granted by the European Commission to Premier Research Group S.L., Spain, for trifarotene (also known as CD5789) for the treatment of autosomal recessive congenital ichthyosis.

Key facts

Active substance
Trifarotene
Disease / condition
Treatment of autosomal recessive congenital ichthyosis
Date of first decision
24/03/2020
Outcome
Positive
EU designation number
EU/3/20/2264

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Premier Research Group S.L.
Camino De La Zarzuela 19
28023 Madrid
Spain
Tel. +34 91038 8900
E-mail: orphandrugs@premier-research.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating